• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Evogene Ltd

    10/15/24 6:52:26 AM ET
    $EVGN
    Agricultural Chemicals
    Industrials
    Get the next $EVGN alert in real time by email
    SC 13G/A 1 tm2426101d1_sc13ga.htm SC 13G/A

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934
    (Amendment No. _1)*

     

    Evogene Ltd.

    (Name of Issuer)

     

    Common Stock

    (Title of Class of Securities)

     

    M4119S104

    (CUSIP Number)

     

    October 11, 2024

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    x  Rule 13d-1(b)
    ¨  Rule 13d-1(c)
    ¨  Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

      

    CUSIP No. M4119S104 13G Page 2 of 10

     

    1.

    NAMES OF REPORTING PERSONS

     

    SilverArc Capital Management, LLC

    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    ¨
    (b)    ¨
    3.

    SEC USE ONLY

     

    4. CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5. SOLE VOTING POWER
     
    0
    6. SHARED VOTING POWER
     
    307,972
    7. SOLE DISPOSITIVE POWER
     
    0
    8. SHARED DISPOSITIVE POWER
     
    307,972
    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    307,972

    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)    ¨
    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    3.52%

    12.

    TYPE OF REPORTING PERSON (see instructions)

     

    IA

           

     

     

     

     

    CUSIP No. M4119S104 13G Page 3 of 10

     

    1.

    NAMES OF REPORTING PERSONS

     

    Devesh Gandhi

    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    ¨
    (b)    ¨
    3.

    SEC USE ONLY

     

    4. CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5. SOLE VOTING POWER
     
    0
    6. SHARED VOTING POWER
     
    307,972
    7. SOLE DISPOSITIVE POWER
     
    0
    8. SHARED DISPOSITIVE POWER
     
    307,972
    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    307,972

    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)    ¨
    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    3.52%

    12.

    TYPE OF REPORTING PERSON (see instructions)

     

    IN

           

     

     

     

     

    CUSIP No. M4119S104 13G Page 4 of 10

     

    Item 1.

     

    (a)Name of Issuer

     

    Evogene Ltd.

     

    (b)Address of Issuer’s Principal Executive Offices

     

    13 Gad Feinstein Street, Park Rehovot, Rehovot, Israel.

     

    Item 2.

     

    (a)Name of Person Filing

     

    SilverArc Capital Management, LLC (“SilverArc”) and Devesh Gandhi (“Gandhi” and together with SilverArc, the “Reporting Persons”)

     

    (b)Address of the Principal Office or, if none, residence

     

    20 Park Plaza, 4th Floor

    Boston, MA 02116

     

    (c)Citizenship

     

    SilverArc is a Delaware limited liability company. Gandhi is a citizen of the United States.

     

    (d)Title of Class of Securities

     

    Common Stock

     

    (e)CUSIP Number

     

    M4119S104

     

     

      

    CUSIP No. M4119S104 13G Page 5 of 10

     

    Item 3. If this statement is filed pursuant to Sec. 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)¨ Broker or dealer registered under section 15 of the Act (15 U.S.D. 78o):

     

    (b)¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

     

    (c)¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

     

    (d)¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);

     

    (e)x An investment adviser in accordance with Sec. 240.13d-1(b)(1)(ii)(E);

     

    (f)¨ An employee benefit plan or endowment fund in accordance with Sec. 240.13d-1(b)(1)(ii)(F);

     

    (g)x A parent holding company or control person in accordance with Sec. 240.13d-1(b)(1)(ii)(G);

     

    (h)¨ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

    (i)¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

     

    (j)¨   A non-U.S. institution in accordance with Sec. 240.13d-1(b)(1)(ii)(J);

     

    (k)¨   Group, in accordance with Sec. 240.13d-1(b)(1)(ii)(J).

     

    Item 4. Ownership

     

    This statement is being filed with respect to an aggregate of 307,972 shares of Common Stock, resulting in beneficial ownership of Common Stock as follows:

     

    1.SilverArc

     

    (a)Amount Beneficially owned: 307,972

     

    (b)Percent of Class: 3.52%.

     

    (c)Number of shares to which the person has:

     

    (i)Sole power to vote or to direct the vote: 0.

     

    (ii)Shared power to vote or to direct the vote: 307,972

     

    (iii)Sole power to dispose or to direct the disposition of: 0.

     

    (iv)Shared power to dispose or to direct the disposition of: 307,972

     

    2.Gandhi

     

    (d)Amount Beneficially owned: 307,972

     

    (e)Percent of Class: 3.52%.

     

    (f)Number of shares to which the person has:

     

    (v)Sole power to vote or to direct the vote: 0.

     

    (vi)Shared power to vote or to direct the vote: 307,972

     

    (vii)Sole power to dispose or to direct the disposition of: 0.

     

    (viii)Shared power to dispose or to direct the disposition of: 307,972.

     

     

     

     

    CUSIP No. M4119S104 13G Page 6 of 10

      

    Item 5. Ownership of Five Percent or Less of a Class.

     

    xAs of the date of this Report, the aggregate beneficial ownership of the Reporting Persons had been reduced to below five percent (5%).

     

    Item 6. Ownership of More than Five Percent on Behalf of another Person.

     

    SilverArc, an investment adviser registered under Section 203 of the Investment Advisers Act of 1940, is deemed to be the beneficial owner of 307,972 shares, or 3.52% of the Common Stock believed to be outstanding, as a result of acting as investment adviser to various clients. Gandhi is the Sole Member of SilverArc and as such is deemed to be the beneficial owner of 307,972 shares, or 3.52% of the Common Stock believed to be outstanding.  Clients of SilverArc have the right to receive and the ultimate power to direct the receipt of dividends from, or the proceeds of the sale of, such securities. SilverArc Capital Alpha Fund I, L.P., a Delaware limited partnership for which SilverArc acts as an investment adviser, may be deemed to beneficially own 8,932 of these 307,972 shares, which equates to 0.10% of the Common Stock believed to be outstanding. SilverArc Capital Alpha Fund II, L.P., a Delaware limited partnership for which SilverArc acts as an investment adviser, may be deemed to beneficially own 194,692 of these 307,972 shares, which equates to 2.23% of the Common Stock believed to be outstanding. Squarepoint Diversified Partners Fund Limited, a Cayman Island exempted company for which SilverArc acts as investment adviser, may be deemed to beneficially own 69,593 of these 307,972 shares, which equates to 0.80% of the Common Stock believed to be outstanding. Atom Master Fund L.P., a Cayman Islands exempted limited partnership for which SilverArc acts as investment adviser, may be deemed to beneficially own 34,755 of these 307,972 shares, which equates to 0.40% of the Common Stock believed to be outstanding.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

     

    Not Applicable

     

    Item 8. Identification and Classification of Members of the Group.

     

    Not Applicable

     

    Item 9. Notice of Dissolution of Group.

     

    Not Applicable

     

     

     

     

    CUSIP No. M4119S104 13G Page 7 of 10

     

    Item 10. Certification

     

    By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    Exhibits.

     

    Exhibit A      Joint Filing Agreement by and between the Reporting Persons dated October 11, 2024.

     

     

     

      

    CUSIP No. M4119S104 13G Page 8 of 10

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      October 15, 2024
      Date

     

    /s/ Devesh S. Gandhi  
    Devesh S. Gandhi, as Sole Member of SilverArc Capital Management, LLC  

     

    /s/ Devesh S. Gandhi  
    Devesh S. Gandhi  

     

     

     

     

    CUSIP No. M4119S104 13G Page 9 of 10

     

    EXHIBIT INDEX

     

    Ex. Page No.
       
    A Joint Filing Agreement 10

     

     

     

     

    CUSIP No. M4119S104 13G Page 10 of 10

     

    EXHIBIT A

     

    JOINT FILING AGREEMENT

     

    The undersigned hereby agree that the statement on Schedule 13G with respect to the common stock of Evogene Ltd., dated as of October 11, 2024, is, and any amendments thereto (including amendments on Schedule 13D) signed by each of the undersigned shall be, filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended.

     

      October 15, 2024
      Date

     

    /s/ Devesh S. Gandhi  
    Devesh S. Gandhi, as Sole Member of SilverArc Capital Management, LLC  

     

    /s/ Devesh S. Gandhi  
    Devesh S. Gandhi  

     

     

     

    Get the next $EVGN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EVGN

    DatePrice TargetRatingAnalyst
    11/24/2021$8.00 → $7.00Outperform
    RBC Capital
    10/8/2021$7.00Buy
    ROTH Capital
    8/23/2021$8.00Outperform
    RBC Capital
    7/29/2021$10.00Buy
    Aegis Capital
    More analyst ratings